

World Journal of *Gastrointestinal Surgery*

World J Gastrointest Surg 2017 December 27; 9(12): 233-292



REVIEW

- 233 Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma
Ziogas IA, Tsoulfas G
- 246 Role of oral antibiotics for prophylaxis against surgical site infections after elective colorectal surgery
Cawich SO, Teelucksingh S, Hassranah S, Naraynsingh V

ORIGINAL ARTICLE

Retrospective Study

- 256 Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy
Hasan S, Thai N, Uemura T, Kudithipudi V, Renz P, Abel S, Kirichenko AV
- 264 Utility of single-incision totally extraperitoneal inguinal hernia repair with intraperitoneal inspection
Yamamoto M, Urushihara T, Itamoto T

Clinical Practice Study

- 270 Risk factors for pancreatic fistula following pancreaticoduodenectomy: A retrospective study in a Thai tertiary center
Rungsakulkij N, Mingphruedhi S, Tangtawee P, Krutsri C, Muangkaew P, Suragul W, Tannaphai P, Aeesoa S

CASE REPORT

- 281 Surgically treated diaphragmatic perforation after radiofrequency ablation for hepatocellular carcinoma
Nagasu S, Okuda K, Kuromatsu R, Nomura Y, Torimura T, Akagi Y
- 288 Ectopic gastrointestinal variceal bleeding with portal hypertension
Minowa K, Komatsu S, Takashina K, Tanaka S, Kumano T, Imura K, Shimomura K, Ikeda J, Taniguchi F, Ueshima Y, Lee T, Ikeda E, Otsuji E, Shioaki Y

Contents

World Journal of Gastrointestinal Surgery
Volume 9 Number 12 December 27, 2017

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Surgery*, Jean-Francois Gigot, MD, Professor, Department of Abdominal Surgery and Transplantation, Saint-Luc University Hospital, Brussels 101200, Belgium

AIM AND SCOPE

World Journal of Gastrointestinal Surgery (*World J Gastrointest Surg*, *WJGS*, online ISSN 1948-9366, DOI: 10.4240) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGS covers topics concerning micro-invasive surgery; laparoscopy; hepatic, biliary, pancreatic and splenic surgery; surgical nutrition; portal hypertension, as well as associated subjects. The current columns of *WJGS* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal surgery diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGS*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING

World Journal of Gastrointestinal Surgery is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, and PubMed Central.

FLYLEAF

I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Li-Jun Cui*
Proofing Editorial Office Director: *Xin-Xia Song*

NAME OF JOURNAL

World Journal of Gastrointestinal Surgery

ISSN

ISSN 1948-9366 (online)

LAUNCH DATE

November 30, 2009

FREQUENCY

Monthly

EDITOR-IN-CHIEF

Timothy M Pawlik, MD, Director, Professor, Department of Surgery, Johns Hopkins University, School of Medical, Baltimore, MD 21287, United States

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1948-9366/editorialboard.htm>

EDITORIAL OFFICE

Xiu-Xia Song, Director

World Journal of Gastrointestinal Surgery

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE

December 27, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION

<http://www.f6publishing.com>

Clinical Practice Study

Risk factors for pancreatic fistula following pancreaticoduodenectomy: A retrospective study in a Thai tertiary center

Narongsak Rungsakulkij, Somkit Mingphruehdi, Pongsatorn Tangtawee, Chonlada Krutsri, Paramin Muangkaew, Wikran Suragul, Penampai Tannaphai, Suraida Aesosa

Narongsak Rungsakulkij, Somkit Mingphruehdi, Pongsatorn Tangtawee, Chonlada Krutsri, Paramin Muangkaew, Wikran Suragul, Suraida Aesosa, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand

Penampai Tannaphai, Department of Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand

ORCID number: Narongsak Rungsakulkij (0000-0003-3522-5800); Somkit Mingphruehdi (0000-0002-1404-1968); Pongsatorn Tangtawee (0000-0001-9598-5479); Chonlada Krutsri (0000-0001-6418-6578); Paramin Muangkaew (0000-0002-2470-8164); Wikran Suragul (0000-0002-9933-9279); Penampai Tannaphai (0000-0002-1873-1771); Suraida Aesosa (0000-0002-4137-3861).

Author contributions: Rungsakulkij N contributed to design of the work, data collection, interpretation of data, writing and drafting the work; Mingphruehdi S, Tangtawee P and Krutsri C contributed to data collection and analysis; Muangkaew P, Suragul W and Tannaphai P contributed to data collection; Aesosa S contributed to data analysis.

Institutional review board statement: The study was reviewed and approved by the Ramathibodi Hospital Institutional Review Board Committee on Human Rights Related to Research Involving Human Subjects. The protocol number is ID 12-59-50.

Informed consent statement: Not applicable.

Conflict-of-interest statement: All authors have no conflict of interest to report.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on

different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Narongsak Rungsakulkij, MD, FRCS (Gen Surg), Lecturer, Surgeon, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Ramathibodi Hospital, 270 Praram VI road, Ratchathewi, Bangkok 10400, Thailand. narongsak.run@mahidol.ac.th
Telephone: +66-2-2011527
Fax: +66-2-2012471

Received: July 24, 2017

Peer-review started: July 26, 2017

First decision: September 11, 2017

Revised: September 15, 2017

Accepted: October 30, 2017

Article in press: October 30, 2017

Published online: December 27, 2017

Abstract

AIM

To analyze the risk factors of postoperative pancreatic fistula following pancreaticoduodenectomy in a Thai tertiary care center.

METHODS

We retrospectively analyzed 179 patients who underwent pancreaticoduodenectomy at our hospital from January 2001 to December 2016. Pancreatic fistula were classified into three categories according to a definition made by an International Study Group on Pancreatic Fistula. The risk factors for pancreatic fistula were analyzed by univariate analysis and multivariate logistic regression analysis.

RESULTS

Pancreatic fistula were detected in 88/179 patients (49%) who underwent pancreaticoduodenectomy. Fifty-eight pancreatic fistula (65.9%) were grade A, 22 cases (25.0%) were grade B and eight cases (9.1%) were grade C. Clinically relevant pancreatic fistula were detected in 30/179 patients (16.7%). The 30-d mortality rate was 1.67% (3/179 patients). Multivariate logistic regression analysis revealed that soft pancreatic texture (odds ratio = 3.598, 95%CI: 1.77-7.32) was the most significant risk factor for pancreatic fistula. A preoperative serum bilirubin level of > 3 mg/dL was the most significant risk factor for clinically relevant pancreatic fistula according to univariate and multivariate analysis.

CONCLUSION

Soft pancreatic tissue is the most significant risk factor for postoperative pancreatic fistula. A high preoperative serum bilirubin level (> 3 mg/dL) is the most significant risk factor for clinically relevant pancreatic fistula.

Key words: Risk factors; Pancreatic fistula; Pancreas; Pancreatectomy; Pancreaticoduodenectomy

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Pancreaticoduodenectomy is a high morbidity operation. The most common perioperative complication is postoperative pancreatic fistula. We retrospectively analyzed 179 patients who underwent pancreaticoduodenectomy at our hospital. We found that soft pancreatic tissue is the most significant risk factor for postoperative pancreatic fistula. A high preoperative serum bilirubin level (> 3 mg/dL) is the most significant risk factor for clinically relevant pancreatic fistula.

Rungsakulkij N, Mingphruedhi S, Tangtawee P, Krutsri C, Muangkaew P, Suragul W, Tannaphai P, Aeesoa S. Risk factors for pancreatic fistula following pancreaticoduodenectomy: A retrospective study in a Thai tertiary center. *World J Gastrointest Surg* 2017; 9(12): 270-280 Available from: URL: <http://www.wjgnet.com/1948-9366/full/v9/i12/270.htm> DOI: <http://dx.doi.org/10.4240/wjgs.v9.i12.270>

INTRODUCTION

Pancreaticoduodenectomy (PD) is the standard treatment for resectable periampullary and pancreatic tumors. PD is an example of major surgery and is a complicated operation to perform for the general surgeon. Current mortality rates are low; previous reports have suggested a perioperative mortality rate of less than 5%^[1-3]. However, high morbidity rates have also been reported, some reaching up to 50%^[3-7]. The most common complication following PD is postoperative pancreatic fistula (POPF). POPF is the major cause of complications

such as delayed gastric emptying (DGE), postoperative hemorrhage, intra-abdominal infection and increased length of hospital stay (LOH)^[8].

Many risk factors have been reported for POPF, including obesity, soft pancreatic texture, small pancreatic duct and low volume center^[9-15]. Some studies have investigated ways to improve the surgical outcome and reduce POPF, including the placement of an external and internal trans-anastomotic pancreatic duct^[16,17], pancreatogastrostomy^[18-20], omental roll-up around pancreaticoenteric (PE) anastomosis^[21], application of fibrin sealants around PE anastomosis^[22,23] and prophylaxis with somatostatin analogs^[24-25]. However, the outcomes of these different methods remain controversial.

Recently, a soft pancreas and high body mass index (BMI) were reported as the most common risk factors for POPF^[9-13]. However, POPF risk factors have not been studied in a Thai population before. The aim of this study was to analyze the risk factors of POPF following PD in a Thai tertiary care center.

MATERIALS AND METHODS

Patients

From January 2001 to December 2016, 210 consecutive patients underwent PD at the Department of Surgery in Ramathibodi Hospital, Bangkok, Thailand and were considered for inclusion in the study. Patients who underwent a concomitant hepatic resection were excluded; in the end, a total of 179 patients were included. Patient data were retrospectively reviewed. These included age, gender, weight, BMI, underlying disease, serum albumin, preoperative total bilirubin levels and preoperative biliary drainage (PBD). In addition, we recorded the use of percutaneous trans-hepatic biliary drainage or placement of an endoscopic internal biliary stent. We also reviewed the type of operation, pancreatic texture, pancreatic duct size, type of PE anastomosis, use of trans-anastomotic pancreatic duct stent, pathological diagnosis, operative time and operative blood loss. Ethical permission for this study was obtained from the hospital's ethics committee.

Preoperative evaluation

The general condition of patients and any co-morbid conditions were preoperatively assessed by a physician, surgeon and internist. The diagnosis and clinical staging of the disease were reviewed preoperatively by a multidisciplinary team including surgeons, radiologists and gastroenterologists.

Operative approach

Routine antibiotic prophylaxis was administered 30 min before the incision. PD is classified into classical PD and pylorus-preserved PD (PPPD) and the type of surgery depended on the surgeon's own preference. Reconstruction after resection was performed using

Child's technique, starting with a pancreaticojejunostomy (PJ). A PJ can be performed using either a invagination or duct to mucosa technique and this was decided based on the surgeon's preference. A trans-anastomotic pancreatic duct stent was placed in selected patients, depending on surgeon's preference. The trans-anastomotic pancreatic duct stent was either internal (in the jejunum) or external (partly outside the body). After PJ, biliary-enteric anastomosis was performed followed by a gastro-jejunostomy or duodeno-jejunostomy. A Braun loop jejunostomy was performed in some patients, according to the surgeon's preference. Pancreatic texture was classified into hard, firm or soft consistency based on palpitation by the surgeon. A closed peri-anastomotic drainage system was placed routinely.

Postoperative complications

After surgery, patients were transferred to a critical care unit or intermediate ward. Routine biochemical analyses of patients' blood were performed. An oral diet was started as soon as the output gastric content was < 400 mL and a positive bowel movement occurred. Parenteral nutrition was initiated if the patients did not have a bowel movement or the gastric content was > 400 mL after postoperative day (POD) 3.

POPF was defined according to International Study Group of Pancreatic Fistula (ISGPF) guidelines by amylase levels that were three times higher in the drainage fluid than the serum. POPFs were classified into three categories: (1) Grade A: Transient pancreatic fistula with no clinical impact; (2) grade B: Required a change in management or adjustment of the clinical course; and (3) grade C: Required a major change in clinical management or deviated from the normal clinical course^[26]. Combined grade B + C fistulas were defined as "clinically relevant pancreatic fistula" (CR-POPF). DGE was defined as either nasogastric tube insertion after POD 3 or as the inability to tolerate solid food intake by POD 7. Chyle leakage was defined as a milky drain output or triglyceride levels of > 110 mg/dL in the drain fluid on any POD. Postoperative mortality was recorded as the 30-d mortality and in-hospital mortality.

Statistical analysis

Patient characteristics were compared by *t*-test, Wilcoxon Mann-Whitney test, χ^2 test and Fisher's exact test. A *P*-value of < 0.05 was considered statistically significant. Risk factors were analyzed by univariate and multivariate methods using binary logistic regression analysis. Independent risk factors were expressed as odds ratios (ORs) with 95%CI.

RESULTS

Patient characteristics and perioperative status

A total of 179 consecutive patients (95 males, 84 females) that underwent PD were included. One hundred and twenty-eight (71.5%) patients had classical PD

and 51 (28.5%) patients had PPPD. Malignancy was diagnosed in 145 patients (79.9%) as follows: 62 ampullary carcinoma patients (44.8%), 40 pancreatic cancer patients (27.6%), 18 cholangiocarcinoma patients (12.4%) and 11 duodenal cancer patients (7.6%) (Table 1).

Patient characteristics and operative outcomes in patients with and without POPF

POPF were detected in 88 patients (49%). Fifty-eight patients (65.9%) had grade A POPF, 22 patients (25%) had grade B POPFs and eight patients (9.1%) had grade C POPFs. CR-POPF were detected in 30/179 patients (16.7%). The 30-d mortality rate was 1.67% (3/179). Table 1 compares the post-PD complications between POPF and no POPF groups. Age, serum albumin levels, operative blood loss, gender, diabetes mellitus and PBD were not statistically different between the two groups. However, statistically significant differences were observed in BMI, preoperative total serum bilirubin, pancreatic duct diameter, operative time, cardiovascular disease, pancreatic texture and trans-anastomotic stent between the two groups. The POPF group had a higher rate of other complications (5.5% vs 25%, *P* < 0.001) and a longer LOH (15 d vs 25 d, *P* < 0.001).

Risk factors for POPF

Univariate and multivariate analyses were used to identify risk factors for POPF (Table 2). Univariate analyses of the 88 patients with pancreatic fistula revealed the following risk factors for POPF: BMI > 25 (OR 2.38, 95%CI: 1.13-5.03, *P* = 0.005), pancreatic duct diameter (OR 2.765, 95%CI: 1.47-5.18, *P* = 0.002), operative time (OR 2.39, 95%CI: 1.26-4.55, *P* = 0.008), history of cardiovascular disease (OR 3.41, 95%CI: 1.48-7.86, *P* = 0.004), soft pancreatic texture (OR 4.682, 95%CI: 2.47-8.87, *P* < 0.001) and placement of a trans-anastomotic pancreatic duct stent (OR 2.55, 95%CI: 1.31-4.99, *P* = 0.006). Multivariate logistic regression analysis revealed soft pancreatic texture (OR 3.59, 95%CI: 3.01-17.35, *P* < 0.001) as the most significant risk factor for POPF.

Effect of POPF grade on patient characteristics and operative outcomes and predictive factors for CR-POPF

Preoperative total bilirubin and pancreatic reconstruction techniques (duct to mucosa vs invagination) were significantly different between grade A POPF and CR-POPF (Table 3). Univariate analysis revealed preoperative total serum bilirubin levels of more than 3 mg/dL as a potential risk factor for grade A POPF (OR 3.749, 95%CI: 1.48-9.51, *P* = 0.005). Multivariate analysis revealed total serum bilirubin levels of more than 3 mg/dL as the most significant predictive factor for CR-POPF (OR 4.50, 95%CI: 1.54-13.15, *P* = 0.006) (Table 4).

DISCUSSION

The most common perioperative complication of PD is

Table 1 Patient characteristics in postoperative pancreatic fistula and no postoperative pancreatic fistula groups

Characteristic data	No POPF (<i>n</i> = 91)	POPF (<i>n</i> = 88)	<i>P</i> -value	95%CI
Age, mean (SD)	60.7 (10.6)	59.1 (11.2)	0.33	58.22-61.44
BMI, median (IQR)	21.4 (20, 23.9)	23.1 (20.8, 25.5)	0.005	22.05-23.22
Albumin, median (IQR)	34.1 (31, 38.3)	34.9 (32, 37.95)	0.667	33.38-35.10
Total bilirubin, median (IQR)	4.1 (1.3, 13.2)	1.3 (0.7, 5.6)	0.002	5.01-7.16
Pancreatic duct diameter (mm), median (IQR)	3 (3, 5)	3 (2, 5)	0.048	3.44-3.99
Operative time, median (IQR)	420 (360, 540)	480 (420, 570)	0.014	448.46-486.23
Blood loss (mL), median (IQR)	1000 (600, 1500)	800 (500, 1500)	0.236	1082-1459.66
LOH day, median (IQR)	15 (12, 20)	25 (17, 39.5)	< 0.001	23.14-32.87
Gender, <i>n</i> (%)				
Male	49 (53.8)	46 (52.3)	0.833	
Female	42 (46.2)	42 (47.7)		
DM, <i>n</i> (%)				
No	64 (70.3)	69 (78.4)	0.216	
Yes	27 (29.7)	19 (21.6)		
Hx of cardiovascular disease, <i>n</i> (%)				
No	82 (90.1)	64 (72.7)	0.003	
Yes	9 (9.9)	24 (27.3)		
PBD, <i>n</i> (%)				
No	36 (39.6)	25 (28.4)	0.116	
Yes	55 (60.4)	63 (71.6)		
Pancreatic texture, <i>n</i> (%) ¹				
Hard/firm	60 (68.2)	27 (31.4)	< 0.001	
Soft	28 (31.8)	59 (68.6)		
Type of resection, <i>n</i> (%)				
PPPD	20 (22.0)	31 (35.2)	0.05	
Classical PD	71 (78.0)	57 (64.8)		
Duct to mucosa <i>vs</i> Invagination				
Duct to mucosa	56 (61.5)	63 (71.6)	0.154	
Invagination	35 (38.5)	25 (28.4)		
Stent, <i>n</i> (%)				
No	73 (80.2)	54 (61.4)	0.005	
Yes	18 (19.8)	34 (38.6)		
External <i>vs</i> Internal, <i>n</i> (%)				
External	4 (22.2)	12 (36.4)	0.298	
Internal	14 (77.8)	21 (63.6)		
Malignant, <i>n</i> (%)				
No	18 (19.8)	16 (18.2)	0.785	
Yes	73 (80.2)	72 (81.8)		
Final diagnosis, <i>n</i> (%)				
CA ampulla	25 (27.5)	37 (42.1)	0.04	
CA pancreas	28 (27.5)	12 (13.6)		
CA duodenal	8 (8.8)	3 (3.4)		
CA distal CBD	7 (7.7)	11 (12.5)		
Other	26 (28.5)	25 (28.4)		
Grading, <i>n</i> (%)				
No	91 (100)	0	0	
A	0	58 (65.9)		
B	0	22 (25.0)		
C	0	8 (9.1)		
Other complications				
No	86 (94.5)	66 (75.0)	< 0.001	
Yes	5 (5.5)	22 (25.0)		
30-d mortality, <i>n</i> (%)				
No	91 (100)	85 (96.6)	0.117	
Yes	0	3 (3.4)		
Age, <i>n</i> (%)				
< 70	73 (80.2)	73 (82.9)	0.637	
≥ 70	18 (19.8)	15 (17.1)		
BMI, <i>n</i> (%)				
< 25	78 (85.7)	63 (71.6)	0.021	
≥ 25	13 (14.3)	25 (28.4)		
Albumin, <i>n</i> (%)				
≥ 30	75 (82.4)	77 (87.5)	0.342	
< 30	16 (17.6)	11 (12.5)		
Total bilirubin, <i>n</i> (%)				
< 3	41 (45.1)	56 (63.6)	0.013	
≥ 3	50 (54.9)	32 (36.4)		

Pancreatic duct diameter, <i>n</i> (%)			
≥ 5	45 (49.4)	23 (26.1)	0.001
< 5	46 (50.6)	65 (73.9)	
Operative time, <i>n</i> (%)			
< 420	39 (42.9)	21 (23.9)	0.007
≥ 420	52 (57.1)	67 (76.1)	
Blood loss, <i>n</i> (%)			
< 1000	45 (49.5)	54 (61.4)	0.109
≥ 1000	46 (50.5)	34 (38.6)	

¹*n* = 174 patients. Other complications: DGE, postoperative hemorrhage, chyle leakage. POPF: Postoperative pancreatic fistula; PBD: Preoperative biliary drainage; PPPD: Pylorus-preserved pancreaticoduodenectomy; PD: Pancreaticoduodenectomy; BMI: Body mass index.

Table 2 Univariate and multivariate logistic regression analysis of postoperative pancreatic fistula risk factors

Variable	Univariate OR (95%CI)	Univariate <i>P</i> -value	Multivariate OR (95%CI)	Multivariate <i>P</i> -value
Age (yr)				
< 70				
≥ 70	0.833 (0.39-1.78)	0.637		
Body mass index (kg/cm ²)				
< 25				
≥ 25	2.381 (1.13-5.03)	0.023	2.081 (0.86-5.03)	0.104
Albumin				
≥ 30				
< 30	0.669 (0.29-1.54)	0.344		
Total bilirubin				
< 3				
≥ 3	0.468 (0.26-0.85)	0.013	1.455 (0.38-5.55)	0.583
Pancreatic duct diameter				
≥ 5 mm				
< 5 mm	2.765 (1.47-5.18)	0.002	3.148 (0.81-12.27)	0.098
Operative time				
< 420 min				
≥ 420 min	2.393 (1.26-4.55)	0.008	1.355 (0.59-3.07)	0.465
Blood loss				
< 1000				
≥ 1000	0.616 (0.34-1.12)	0.11		
Gender				
Male				
Female	1.065 (0.59-1.92)	0.833		
DM				
No				
Yes	0.653 (0.33-1.29)	0.218		
Hx of cardiovascular disease				
No				
Yes	3.417 (1.48-7.86)	0.004	2.612 (0.96-7.08)	0.059
Preop biliary stent (no)				
No				
Yes	1.649 (0.88-3.08)	0.117		
Pancreatic texture				
Hard/firm				
Soft	4.682 (2.47-8.87)	< 0.001	3.598 (1.77-7.32)	< 0.001
Type of resection				
Pylorus-preserved pancreaticoduodenectomy				
Pancreaticoduodenectomy	0.518 (0.27-1.00)	0.051	0.807 (0.37-1.78)	0.597
Duct to mucosa				
Invagination	0.635 (0.34-1.19)	0.156		
Stent (no)				
No				
Yes	2.553 (1.31-4.99)	0.006	1.272 (0.52-3.09)	0.595
External				
Internal	0.500 (0.13-1.87)	0.303		
Malignant (no)				
No				
Yes	1.109 (0.52-2.34)	0.785		
Final diagnosis (CA ampulla)				
CA pancreas	0.324 (0.14-0.76)	0.01	0.439 (0.16-1.19)	0.105
CA duodenal	0.253 (0.06-1.05)	0.058	0.533 (0.11-2.59)	0.435
CA distal CBD	1.062 (0.36-3.11)	0.913	1.188 (0.33-4.29)	0.793
Other	0.650 (0.31-1.37)	0.258	0.543 (0.22-1.35)	0.189

Table 3 Relationships between patient characteristics, operative outcome and postoperative pancreatic fistula grade

Characteristic data	POPF (grading)		P-value	95%CI
	A (n = 58)	B + C (n = 30)		
Age, mean (SD)	59.2 (11.3)	58.8 (11.4)	0.874	56.67-61.46
Body mass index, median (IQR)	23.1 (20.4, 25.1)	23.1 (21.1, 26.5)	0.805	22.62-24.45
Albumin, median (IQR)	34.7 (32, 38)	35.4 (32, 37.9)	0.603	33.38-35.58
Total bilirubin, median (IQR)	0.9 (2, 5)	3.3 (1.2, 12)	0.01	3.44-6.66
Pancreatic duct diameter (mm), median (IQR)	3 (2, 5)	3 (2, 4)	0.175	3.07-3.79
Operative time, median (IQR)	480 (420, 600)	480 (360, 540)	0.49	462.22-511.75
Blood loss (mL), median (IQR)	800 (500, 1500)	900 (600, 1500)	0.071	985.10-1616.95
LOH day, median (IQR)	21 (14, 30)	42.5 (30, 60)	< 0.001	28.14-46.32
Gender, n (%)				
Male	34 (58.6)	12 (40.0)	0.097	
Female	24 (41.4)	18 (60.0)		
DM, n (%)				
No	45 (77.6)	24 (80.0)	0.794	
Yes	13 (22.4)	6 (20.0)		
Hx of cardiovascular disease, n (%)				
No	42 (72.4)	22 (73.3)	0.927	
Yes	16 (27.6)	8 (26.7)		
PBD, n (%)				
No	20 (34.5)	5 (16.7)	0.079	
Yes	38 (65.5)	25 (83.3)		
Pancreatic texture, n (%)				
Hard/Firm	20 (35.1)	7 (24.1)	0.301	
Soft	37 (64.9)	22 (75.9)		
Type of resection, n (%)				
PPPD	24 (41.4)	7 (23.3)	0.093	
PD	34 (58.6)	23 (76.7)		
Duct, n (%)				
Duct to mucosa	46 (79.3)	17 (56.7)	0.026	
Invagination	12 (20.7)	13 (43.3)		
Stent, n (%)				
No	32 (55.2)	22 (73.3)	0.097	
Yes	26 (44.8)	8 (26.7)		
External vs Internal, n (%)				
External	8 (32.0)	4 (50.0)	0.42	
Internal	14 (68.0)	4 (50.0)		
Malignant, n (%)				
No	12 (20.7)	4 (13.3)	0.396	
Yes	46 (79.3)	26 (86.7)		
Final diagnosis, n (%)				
CA ampulla	23 (39.6)	14 (46.7)	0.33	
CA pancreas	8 (13.8)	4 (13.3)		
CA duodenal	3 (5.2)	0		
CA distal CBD	5 (8.6)	6 (20.0)		
Other	19 (32.8)	6 (20.0)		
Age, n (%)				
< 70	47 (81.0)	26 (86.7)	0.505	
≥ 70	11 (19.0)	4 (13.3)		
BMI, n (%)				
< 25	42 (71.4)	21 (70.0)	0.812	
≥ 25	16 (27.6)	9 (30.0)		
Albumin, n (%)				
≥ 30	50 (86.2)	27 (90.0)	0.743	
< 30	8 (13.8)	3 (10.0)		
Total bilirubin, n (%)				
< 3	43 (74.1)	13 (43.3)	0.004	
≥ 3	15 (28.9)	17 (56.7)		
Pancreatic duct diameter, n (%)				
≥ 5	12 (20.7)	11 (36.7)	0.106	
< 5	46 (79.3)	19 (63.3)		
Operative time, n (%)				
< 420	12 (20.7)	9 (30.0)	0.331	
≥ 420	46 (79.3)	21 (70.0)		
Blood loss, n (%)				
< 1000	37 (63.8)	17 (56.7)	0.515	
≥ 1000	21 (36.2)	13 (43.3)		

POPF: Postoperative pancreatic fistula; PBD: Preoperative biliary drainage; PPPD: Pylorus-preserved pancreaticoduodenectomy; PD: Pancreaticoduodenectomy; BMI: Body mass index.

Table 4 Univariate and multivariate logistic regression analysis of risk factors for clinically relevant-postoperative pancreatic fistula

Variable	Univariate OR (95%CI)	Univariate <i>P</i> -value	Multivariate OR (95%CI)	Multivariate <i>P</i> -value
Age (yr)				
< 70				
≥ 70	0.657 (0.19-2.27)	0.507		
BMI (kg/cm ²)				
< 25				
≥ 25	1.125 (0.43-2.96)	0.812		
Albumin				
≥ 30				
< 30	0.694 (0.17-2.84)	0.611		
Total bilirubin				
< 3				
≥ 3	3.749 (1.48-9.51)	0.005	4.506 (1.54-13.15)	0.006
Pancreatic duct diameter (mm)				
≥ 5				
< 5	0.451 (0.17-1.20)	0.11		
Operative time (min)				
< 420				
≥ 420	0.609 (0.22-1.66)	0.334		
Blood loss				
< 1000				
≥ 1000	1.347 (0.55-3.31)	0.516		
Gender				
Male				
Female	2.125 (0.86-5.22)	0.1		
DM				
No				
Yes	0.865 (0.29-2.56)	0.794		
Hx of cardiovascular disease				
No				
Yes	0.954 (0.35-2.58)	0.927		
Preop biliary stent (no)				
No				
Yes	2.631 (0.87-7.92)	0.085	2.24 (0.67-7.49)	0.191
Pancreatic texture				
Hard/firm				
Soft				
Type of resection				
PPPD				
PD	2.319 (0.86-6.27)		1.787 (0.54-5.92)	0.342
Duct to mucosa				
Invagination	2.931 (1.12-7.67)	0.028	2.837 (0.89-9.08)	0.079
Stent (no)				
No				
Yes	0.447 (0.17-1.17)	0.101		
External				
Internal	0.471 (0.09-2.38)	0.362		
Malignant (no)				
No				
Yes	1.695 (0.50-5.80)	0.4		
Final diagnosis (CA ampulla)				
CA pancreas	0.821 (0.21-3.24)	0.779		
CA duodenal	-	-	-	-
CA distal CBD	1.971 (0.51-7.68)	0.328		
Other	0.519 (0.17-1.61)	0.256		

POPF: Postoperative pancreatic fistula; PBD: Preoperative biliary drainage; PPPD: Pylorus-preserved pancreaticoduodenectomy; PD: Pancreaticoduodenectomy; BMI: Body mass index.

POPF. POPF remains the leading cause of complications such as DGE and postoperative hemorrhage, which increase mortality^[1-3] and the LOH. Many risk factors for POPF have been reported previously^[4-9]. In the present study, the incidence of POPF and the 30-d mortality rate were similar to previous studies. In addition, we identified soft pancreatic texture as a main risk factor

for POPF^[8-12].

Our multivariate analysis showed that a soft pancreas is the most independent predictive factor for POPF. This is in agreement with previous studies^[5,9-12,27]. There are many reasons why soft pancreatic tissue increases the risk of POPF. First, a soft pancreas makes it more difficult to secure PEA because friable pancreatic tissue cannot

hold suture tension. As a result, suture materials cut through the pancreatic parenchyma and anastomosis fails. A soft pancreas is also prone to ischemia when manipulated, which disrupts anastomosis. Finally, a soft pancreas has enriched exocrine function and pancreatic enzymes are released when leakage occurs^[9,11,27,28].

The assessment of pancreatic texture is controversial and subjective. Pancreatic texture is commonly assessed intraoperatively by palpation. Callery *et al.*^[11] reported the clinical risk score for POPF based on pancreatic texture, pancreatic duct diameter and intraoperative blood loss. They classified the pancreatic texture as firm or soft^[11]. Some studies have classified pancreatic texture as hard, firm or soft, but the distinction between a hard and firm pancreas remains unclear^[1,5].

Recently, Ansorge *et al.*^[29] reported similar risk factors for POPF. They classified the pancreatic texture into four grades, including very hard (severe chronic pancreatitis), hard (fibrotic or atrophic obstructed pancreatic gland), soft (unaffected compact gland), and very soft (unaffected fatty pancreas). They found that 44/100 patients had a hard pancreas. The rate of POPF in the very hard/hard groups was significantly different to that in the soft/very soft groups^[29]. There is a newly developed tissue strain imaging technology reflecting tissue fibrosis or stiffness and is integrated into a conventional ultrasound system called acoustic radiation force impulse (ARFI). Lee *et al.*^[30] and Harada *et al.*^[30] reported the high accuracy of ARFI for prediction of the stiffness of pancreas preoperatively.

The relationship between soft and fatty pancreatic tissue has been well studied^[28-29,32]. A fatty pancreas refers to the increasing infiltration of adipose tissue into the pancreas^[28]. Ansorge *et al.*^[29] found that the softness of pancreatic tissue was strongly associated with fat levels in the tissue. This was supported by previous reports that a fatty pancreas is a risk factor for POPF^[13,28,32]. Taken together, these findings suggest that the infiltration of adipose tissue into the pancreas is associated with soft pancreatic texture.

The assessment of pancreatic texture is difficult and subjective. Currently, there are no standard procedures for the intraoperative assessment of pancreatic texture. Pancreatic texture has commonly been assessed intraoperatively by palpation^[5,11,29]. In the present study, we also assessed pancreatic texture by palpation. This subjective assessment of pancreatic texture could have differed from surgeon to surgeon.

Unfortunately, it was not possible to assess pancreatic texture during the preoperative evaluation. Tranchart *et al.*^[33] used computed tomography to predict the occurrence of severe pancreatic fistula following PD. They found that a visceral fat area of more than 84 cm³ was associated with a fatty pancreas (58.4% vs 48.1%, $P = 0.005$) and was a risk factor for CR-POPF (OR 8.16 95%CI: 2.2-3, $P = 0.002$). They suggested preoperative assessment of body fat distribution as a means of evaluating fat levels in the pancreas and predicting the occurrence of CR-POPF^[33]. In our study, the incidence of CR-POPF is high when compared to

previous studies^[5,6,11,12]. This could be explained by the lower population of pancreatic cancer in this study that the pancreatic cancer is more likely to obstruct the pancreatic duct and therefore increase fibrosis of the pancreas^[11].

Obstructive jaundice was previously regarded as the main factor increasing perioperative morbidity and mortality. The pathophysiology of obstructive jaundice includes increasing endotoxin concentrations in the portal circulation, altered Kupffer cell function affecting the reticuloendothelial system in the liver, over-activation of inflammatory cascades, decreased cellular immunity and renal dysfunction. These manifestations influence the nutritional status of patients. PBD decreased postoperative septic complications in mice by improving liver function, nutritional status, cell-mediated immune function, systemic endotoxemia, cytokine release and the overall immune response^[34]. Regarding perianastomotic obstruction, endoscopic drainage approach today represents the procedure of choice with high success rate^[35,36].

In this study, a preoperative serum bilirubin level of more than 3 mg/dL was a risk factor for CR-POPF. Kimura *et al.*^[3] reported that serum bilirubin of more than 2.0 mg/dL was a significant preoperative risk factor for higher 30-d and in-hospital mortality rates following PD^[3]. Gebauer *et al.*^[37] found that patients with POPF who underwent repeated surgery had higher in-hospital mortality (0.6 vs 0.7, $P = 0.002$) and total serum bilirubin levels (0.7 vs 1.1, $P = 0.003$) than POPF patients that did not undergo reoperation). In a previous study, multivariate binary logistic regression model analysis revealed that a serum bilirubin level of > 2.0 mg/dL is an independent risk factor for reoperation (OR 25.053, 95%CI: 3.486-180.069)^[37]. Some previous studies have identified higher serum bilirubin levels in CR-POPF patients, but these differences were not statistically significant. For example, El Nakeeb *et al.*^[12] reported a preoperative bilirubin level of 4.6 mg/dL in patients with grade A POPF and 9.7 mg/dL in patients with CR-POPF, but this difference was not significant. This was supported by Braga *et al.*^[38], who detected higher total serum bilirubin in patients with grade III-IV complications than patients with grade 0-II complications (3.5 mg/dL vs 1.6 mg/dL). Again, this difference was not statistically significant. Fujii *et al.*^[39] found that endoscopic internal drainage posed a higher risk for POPF than endoscopic nasobiliary drainage.

In a recent systematic review, Scheufele *et al.*^[40] reported that POPF rates do not differ between PBD and no drainage groups. However, a higher infectious complications rate was detected in the PBD group. Most of the studies included in this review were retrospective studies, and the most frequent complications were wound-related^[40]. A few randomized control trial studies have now been performed by a Dutch group. In these studies, the POPF rate did not differ between PBD and surgery first groups following PD. However, the population in the POPF group was only 16%, which may

not have been high enough to obtain sufficient statistical power^[31]. Current evidence does not recommend routine PBD because the rate of infectious (usually wound-related) complications is higher. However, a randomized control trial of a large population is needed to clarify this in the case of CR-POPF.

In this study, 66.8% of patients underwent PBD, which is higher than previous reports^[39-41]. This could be explained by the fact that Thailand is a low to mid-income country, therefore patients with periampullary tumor and pancreatic cancer usually present with severe obstructive jaundice and have poor nutritional status. Serum bilirubin levels were higher than 15 mg/dL and serum albumin levels were less than 30 mg/dL in most patients. In addition, high-volume centers have patient congestion, limited resources and long waiting lists for operations.

This study was limited by the small study population. A larger population study might have revealed more significant risk factors of POPF.

In conclusion, we have identified a soft pancreas as an independent risk factor of POPF. A fatty pancreas is strongly associated with a soft pancreas and can be measured to predict CR-POPF. Preoperative detection of a fatty pancreas by CT and newly developed ultrasound technology is a potential method for predicting a soft pancreas preoperatively. However, this needs to be confirmed by large population studies. At the moment, PBD is not routinely recommended because the rate of infectious complications is higher. Further studies are required to clarify the link between preoperative obstructive jaundice and CR-POPF.

ARTICLE HIGHLIGHTS

Research background

Many risk factors have been reported for postoperative pancreatic fistula (POPF), including obesity, soft pancreatic texture, small pancreatic duct and low volume center. Some studies have investigated ways to improve the surgical outcome and reduce POPF, including the placement of an external and internal trans-anastomotic pancreatic duct, pancreatogastrostomy, omental roll-up around pancreatocenteric (PE) anastomosis, application of fibrin sealants around PE anastomosis and prophylaxis with somatostatin analogs. However, the outcomes of these different methods remain controversial. Recently, a soft pancreas and high body mass index (BMI) were reported as the most common risk factors for POPF. However, POPF risk factors have not been studied in a Thai population before. The aim of this study was to analyze the risk factors of POPF following PD in a Thai tertiary care center.

Research motivation

The most common perioperative complication of pancreaticoduodenectomy is POPF. POPF remains the leading cause of complications such as DGE and postoperative hemorrhage, which increase mortality and the LOH. Many risk factors for POPF have been reported previously.

Research objectives

The aim of this study was to analyze the risk factors of POPF following PD in a Thai tertiary care center.

Research methods

The retrospective study design were required by reviewed data from January 2001 to December 2016, 210 consecutive patients underwent PD at the

Department of Surgery in Ramathibodi Hospital, Bangkok, Thailand.

Research results

This is the study from tertiary care center from Thailand. To the best of the authors knowledge, this is the largest study from Thailand. The authors found that soft pancreatic tissue is the most significant risk factor for postoperative pancreatic fistula. A high preoperative serum bilirubin level (> 3 mg/dL) is the most significant risk factor for clinically relevant pancreatic fistula.

Research conclusions

The authors have identified a soft pancreas as an independent risk factor of POPF. A fatty pancreas is strongly associated with a soft pancreas and can be measured to predict CR-POPF. Preoperative detection of a fatty pancreas by CT is a potential method for predicting a soft pancreas preoperatively. Recently, the newly developed technology of ultrasonography have high accuracy to prediction of the stiffness of pancreas preoperatively. However, this needs to be confirmed by large population studies. At the moment, PBD is not routinely recommended because the rate of infectious complications is higher. Further studies are required to clarify the link between preoperative obstructive jaundice and CR-POPF.

Research perspectives

Preoperative detection of a fatty pancreas by CT and newly developed ultrasound technology is a potential method for predicting a soft pancreas preoperatively. which needs to be confirmed by large population studies. At the moment, PBD is not routinely recommended because the rate of infectious complications is higher. Further studies are required to clarify the link between preoperative obstructive jaundice and CR-POPF.

ACKNOWLEDGMENTS

The authors would thank Mr. Napaphat Poprom for reviewed the biostatistics.

REFERENCES

- 1 **McMillan MT**, Vollmer CM Jr, Asbun HJ, Ball CG, Bassi C, Beane JD, Berger AC, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, McElhany AL, Salem RR, Soares K, Sprys MH, Valero V 3rd, Watkins AA, Wolfgang CL, Behrman SW. The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy. *J Gastrointest Surg* 2016; **20**: 262-276 [PMID: 26162925 DOI: 10.1007/s11605-015-2884-2]
- 2 **Hackert T**, Hinz U, Pausch T, Fesenbeck I, Strobel O, Schneider L, Fritz S, Büchler MW. Postoperative pancreatic fistula: We need to redefine grades B and C. *Surgery* 2016; **159**: 872-877 [PMID: 26603847 DOI: 10.1016/j.surg.2015.09.014]
- 3 **Kimura W**, Miyata H, Gotoh M, Hirai I, Kenjo A, Kitagawa Y, Shimada M, Baba H, Tomita N, Nakagoe T, Sugihara K, Mori M. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. *Ann Surg* 2014; **259**: 773-780 [PMID: 24253151 DOI: 10.1097/SLA.0000000000000263]
- 4 **Roberts KJ**, Sutcliffe RP, Marudanayagam R, Hodson J, Isaac J, Muiesan P, Navarro A, Patel K, Jah A, Napetti S, Adair A, Lazaridis S, Prachalias A, Shingler G, Al-Sarireh B, Storey R, Smith AM, Shah N, Fusai G, Ahmed J, Abu Hilal M, Mirza DF. Scoring System to Predict Pancreatic Fistula After Pancreatoduodenectomy: A UK Multicenter Study. *Ann Surg* 2015; **261**: 1191-1197 [PMID: 25371115 DOI: 10.1097/SLA.0000000000000997]
- 5 **Addeo P**, Delpero JR, Paye F, Oussoultzoglou E, Fuchshuber PR, Sauvanet A, Sa Cunha A, Le Treut YP, Adham M, Mabrut JY, Chiche L, Bachellier P; French Surgical Association (AFC). Pancreatic fistula after a pancreaticoduodenectomy for ductal adenocarcinoma and its association with morbidity: a multicentre study of the French Surgical Association. *HPB (Oxford)* 2014; **16**: 46-55 [PMID: 23461663 DOI: 10.1007/s11605-013-2346-3]

- 10.1111/hpb.12063]
- 6 **Büchler MW**, Friess H, Wagner M, Kulli C, Wagnen V, Z'Graggen K. Pancreatic fistula after pancreatic head resection. *Br J Surg* 2000; **87**: 883-889 [PMID: 10931023 DOI: 10.1046/j.1365-2168.2000.01465.x]
- 7 **Cameron JL**, He J. Two thousand consecutive pancreaticoduodenectomies. *J Am Coll Surg* 2015; **220**: 530-536 [PMID: 25724606 DOI: 10.1016/j.jamcollsurg.2014.12.031]
- 8 **Frymerman AS**, Schuld J, Ziehen P, Kollmar O, Justinger C, Merai M, Richter S, Schilling MK, Moussavian MR. Impact of postoperative pancreatic fistula on surgical outcome—the need for a classification-driven risk management. *J Gastrointest Surg* 2010; **14**: 711-718 [PMID: 20094814 DOI: 10.1007/s11605-009-1147-5]
- 9 **Hu BY**, Wan T, Zhang WZ, Dong JH. Risk factors for postoperative pancreatic fistula: Analysis of 539 successive cases of pancreaticoduodenectomy. *World J Gastroenterol* 2016; **22**: 7797-7805 [PMID: 27678363 DOI: 10.3748/wjg.v22.i34.7797]
- 10 **Fang CH**, Chen QS, Yang J, Xiang F, Fang ZS, Zhu W. Body Mass Index and Stump Morphology Predict an Increased Incidence of Pancreatic Fistula After Pancreaticoduodenectomy. *World J Surg* 2016; **40**: 1467-1476 [PMID: 26796886 DOI: 10.1007/s00268-016-3413-5]
- 11 **Callery MP**, Pratt WB, Kent TS, Chaikof EL, Vollmer CM Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. *J Am Coll Surg* 2013; **216**: 1-14 [PMID: 23122535 DOI: 10.1016/j.jamcollsurg.2012.09.002]
- 12 **El Nakeeb A**, Salah T, Sultan A, El Hemaly M, Askr W, Ezzat H, Hamdy E, Atef E, El Hanafy E, El-Geidie A, Abdel Wahab M, Abdallah T. Pancreatic anastomotic leakage after pancreaticoduodenectomy. Risk factors, clinical predictors, and management (single center experience). *World J Surg* 2013; **37**: 1405-1418 [PMID: 23494109 DOI: 10.1007/s00268-013-1998-5]
- 13 **Gaujoux S**, Cortes A, Couvelard A, Noullet S, Clavel L, Rebours V, Lévy P, Sauvanet A, Ruzsniowski P, Belghiti J. Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. *Surgery* 2010; **148**: 15-23 [PMID: 20138325 DOI: 10.1016/j.surg.2009.12.005]
- 14 **Akamatsu N**, Sugawara Y, Komagome M, Shin N, Cho N, Ishida T, Ozawa F, Hashimoto D. Risk factors for postoperative pancreatic fistula after pancreaticoduodenectomy: the significance of the ratio of the main pancreatic duct to the pancreas body as a predictor of leakage. *J Hepatobiliary Pancreat Sci* 2010; **17**: 322-328 [PMID: 20464562 DOI: 10.1007/s00534-009-0248-6]
- 15 **Reames BN**, Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and operative mortality in the modern era. *Ann Surg* 2014; **260**: 244-251 [PMID: 24368634 DOI: 10.1097/SLA.0000000000000375]
- 16 **Jang JY**, Chang YR, Kim SW, Choi SH, Park SJ, Lee SE, Lim CS, Kang MJ, Lee H, Heo JS. Randomized multicentre trial comparing external and internal pancreatic stenting during pancreaticoduodenectomy. *Br J Surg* 2016; **103**: 668-675 [PMID: 27040594 DOI: 10.1002/bjs.10160]
- 17 **Dong Z**, Xu J, Wang Z, Petrov MS. Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy. *Cochrane Database Syst Rev* 2016; **(5)**: CD008914 [PMID: 27153248 DOI: 10.1002/14651858.CD008914.pub3]
- 18 **Menahem B**, Guittet L, Mulliri A, Alves A, Lubrano J. Pancreaticogastrostomy is superior to pancreaticojejunostomy for prevention of pancreatic fistula after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. *Ann Surg* 2015; **261**: 882-887 [PMID: 24979604 DOI: 10.1097/SLA.0000000000000806]
- 19 **Topal B**, Fieuws S, Aerts R, Weerts J, Feryn T, Roeyen G, Bertrand C, Hubert C, Janssens M, Closset J; Belgian Section of Hepatobiliary and Pancreatic Surgery. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. *Lancet Oncol* 2013; **14**: 655-662 [PMID: 23643139 DOI: 10.1016/S1470-2045(13)70126-8]
- 20 **Xiong JJ**, Tan CL, Szatmary P, Huang W, Ke NW, Hu WM, Nunes QM, Sutton R, Liu XB. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. *Br J Surg* 2014; **101**: 1196-1208 [PMID: 25042895 DOI: 10.1002/bjs.9553]
- 21 **Tian Y**, Ma H, Peng Y, Li G, Yang H. Preventive effect of omental flap in pancreaticoduodenectomy against postoperative complications: a meta-analysis. *Hepatogastroenterology* 2015; **62**: 187-189 [PMID: 25911894]
- 22 **Barakat O**, Ozaki CF, Wood RP. Topically applied 2-octyl cyanoacrylate (Dermabond) for prevention of postoperative pancreatic fistula after pancreaticoduodenectomy. *J Gastrointest Surg* 2012; **16**: 1499-1507 [PMID: 22580842 DOI: 10.1007/s11605-012-1908-4]
- 23 **Cheng Y**, Ye M, Xiong X, Peng S, Wu HM, Cheng N, Gong J. Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. *Cochrane Database Syst Rev* 2016; **2**: CD009621 [PMID: 26876721 DOI: 10.1002/14651858.CD009621.pub2]
- 24 **Gurusamy KS**, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. *Cochrane Database Syst Rev* 2013; **(4)**: CD008370 [PMID: 23633353 DOI: 10.1002/14651858.CD008370.pub3]
- 25 **Gans SL**, van Westreenen HL, Kiewiet JJ, Rauws EA, Gouma DJ, Boermeester MA. Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. *Br J Surg* 2012; **99**: 754-760 [PMID: 22430616 DOI: 10.1002/bjs.8709]
- 26 **Bassi C**, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M; International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. *Surgery* 2005; **138**: 8-13 [PMID: 16003309 DOI: 10.1016/j.surg.2005.05.001]
- 27 **Lin JW**, Cameron JL, Yeo CJ, Riall TS, Lillemoe KD. Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. *J Gastrointest Surg* 2004; **8**: 951-959 [PMID: 15585382 DOI: 10.1016/j.gassur.2004.09.044]
- 28 **Mathur A**, Pitt HA, Marine M, Saxena R, Schmidt CM, Howard TJ, Nakeeb A, Zyromski NJ, Lillemoe KD. Fatty pancreas: a factor in postoperative pancreatic fistula. *Ann Surg* 2007; **246**: 1058-1064 [PMID: 18043111 DOI: 10.1097/SLA.0b013e31814a6906]
- 29 **Ansorge C**, Strömmer L, Andrén-Sandberg Å, Lundell L, Herrington MK, Segersvärd R. Structured intraoperative assessment of pancreatic gland characteristics in predicting complications after pancreaticoduodenectomy. *Br J Surg* 2012; **99**: 1076-1082 [PMID: 22556164 DOI: 10.1002/bjs.8784]
- 30 **Lee TK**, Kang CM, Park MS, Choi SH, Chung YE, Choi JY, Kim MJ. Prediction of postoperative pancreatic fistulas after pancreatectomy: assessment with acoustic radiation force impulse elastography. *J Ultrasound Med* 2014; **33**: 781-786 [PMID: 24764332 DOI: 10.7863/ultra.33.5.781]
- 31 **Harada N**, Ishizawa T, Inoue Y, Aoki T, Sakamoto Y, Hasegawa K, Sugawara Y, Tanaka M, Fukayama M, Kokudo N. Acoustic radiation force impulse imaging of the pancreas for estimation of pathologic fibrosis and risk of postoperative pancreatic fistula. *J Am Coll Surg* 2014; **219**: 887-894 [PMID: 25262282 DOI: 10.1016/j.jamcollsurg.2014.07.940]
- 32 **Rosso E**, Casnedi S, Pessaux P, Oussoultzoglou E, Panaro F, Mahfud M, Jaek D, Bachellier P. The role of "fatty pancreas" and of BMI in the occurrence of pancreatic fistula after pancreaticoduodenectomy. *J Gastrointest Surg* 2009; **13**: 1845-1851 [PMID: 19639369 DOI: 10.1007/s11605-009-0974-8]
- 33 **Tranchart H**, Gaujoux S, Rebours V, Vullierme MP, Dokmak S, Levy P, Couvelard A, Belghiti J, Sauvanet A. Preoperative CT scan helps to predict the occurrence of severe pancreatic fistula after pancreaticoduodenectomy. *Ann Surg* 2012; **256**: 139-145 [PMID: 22609844 DOI: 10.1097/SLA.0b013e318256c32c]
- 34 **van der Gaag NA**, Kloek JJ, de Castro SM, Busch OR, van Gulik TM, Gouma DJ. Preoperative biliary drainage in patients with obstructive jaundice: history and current status. *J Gastrointest Surg* 2009; **13**: 814-820 [PMID: 18726134 DOI: 10.1007/s11605-008-0618-4]
- 35 **Iacono C**, Ruzzenente A, Campagnaro T, Bortolasi L, Valdegamberi A, Guglielmi A. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. *Ann Surg* 2013; **257**: 191-204 [PMID: 23013805 DOI: 10.1097/SLA.0b013e31826f4b0e]
- 36 **Inamdar S**, Slattery E, Bhalla R, Sejal DV, Trindade AJ. Comparison

- of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort. *JAMA Oncol* 2016; **2**: 112-117 [PMID: 26513013 DOI: 10.1001/jamaoncol.2015.3670]
- 37 **Gebauer F**, Kloth K, Tachezy M, Vashist YK, Cataldegirmen G, Izbicki JR, Bockhorn M. Options and limitations in applying the fistula classification by the International Study Group for Pancreatic Fistula. *Ann Surg* 2012; **256**: 130-138 [PMID: 22504279 DOI: 10.1097/SLA.0b013e31824f24e4]
 - 38 **Braga M**, Capretti G, Pecorelli N, Balzano G, Doglioni C, Ariotti R, Di Carlo V. A prognostic score to predict major complications after pancreaticoduodenectomy. *Ann Surg* 2011; **254**: 702-707; discussion 707-708 [PMID: 22042466 DOI: 10.1097/SLA.0b013e31823598fb]
 - 39 **Fujii T**, Yamada S, Suenaga M, Kanda M, Takami H, Sugimoto H, Nomoto S, Nakao A, Kodera Y. Preoperative internal biliary drainage increases the risk of bile juice infection and pancreatic fistula after pancreatoduodenectomy: a prospective observational study. *Pancreas* 2015; **44**: 465-470 [PMID: 25423556 DOI: 10.1097/MPA.0000000000000265]
 - 40 **Scheufele F**, Schorn S, Demir IE, Sargut M, Tieftrunk E, Calavrezos L, Jäger C, Friess H, Ceyhan GO. Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature. *Surgery* 2017; **161**: 939-950 [PMID: 28043693 DOI: 10.1016/j.surg.2016.11.001]
 - 41 **van der Gaag NA**, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, Gerritsen JJ, Greve JW, Gerhards MF, de Hingh IH, Klinkenbijn JH, Nio CY, de Castro SM, Busch OR, van Gulik TM, Bossuyt PM, Gouma DJ. Preoperative biliary drainage for cancer of the head of the pancreas. *N Engl J Med* 2010; **362**: 129-137 [PMID: 20071702 DOI: 10.1056/NEJMoa0903230]

P- Reviewer: Chow WK, Gong JS, Smith RC **S- Editor:** Kong JX
L- Editor: A **E- Editor:** Lu YJ





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

